ATNM ▲ +4.2% - Actinium Pharmaceuticals, Inc. $ATNM ATNM ATNM - Actinium Pharmaceuticals Announces Oral Presentation at EANM 2026 Highlighting First-in-Human Phase 1 Study of ATNM-400, a Non-PSMA Targeting Radiotherapy, in Prostate Cancer 15-OCT-2026 08:30 AM ET